2,2',2'',2'''-[(4,8-Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol
2. 本品高劑量可提高血小板Cyclic AMP的形成，故又可阻斷ADP誘發的凝集反應，而抑制血小板的粘著凝集，故能防止血栓的形成。
2. 用量：慢性狹心症患者一次25mg，一日三次。
Absorption
Two minutes after a 4 min IV infusion, the mean serum level is 4.6 mcg/mL.
Distribution
Highly bound to plasma protein (99%). Vd is 1 to 2.5 L/kg.
Metabolism
Metabolized in the liver (conjugated as a glucuronide).
Elimination
Excreted in the bile. Average total body Cl is 2.3 to 3.5 mL/min/kg. The alpha t½ (initial decline following Cmax ) is about 40 min, while the beta t½ (terminal decline in plasma level) is approximately 10 h (oral). Triexponential: the t½ range is 3 to 13 min, 33 to 62 min, and 11.6 h (IV).
Peak
The average time to C max is about 75 min.
Adenosine
Plasma levels of adenosine may be elevated, increasing the CV effects.
Cholinesterase inhibitors
Anticholinesterase effects may be counteracted by dipyridamole, potentially aggravating myasthenia gravis.
Theophyllines, xanthine derivatives (eg, caffeine)
May abolish coronary vasodilation induced by IV dipyridamole.
本品若同時併用吉林參、吉林參鬚、高麗參、西洋參併用，可能會降低抗凝血作用。
2. 本藥無法減輕急性心絞痛發作之痛楚，但有助於發作之防止及減少。
3. 本藥用於心絞痛之預防上，達到充分療效可能需時2-3個月。
4. 高達800mg之每日劑量曾被用於心瓣膜(Cardiac valvular)及腎臟外科手術後減少血小板之凝集。
5. 在使用口服抗凝血劑時，每日服用本藥高達400mg，不會影響到Prothrombin之活性及出血時間。
6. 投用本藥時，如從躺臥或坐姿起立時應加小心。
7. 用藥過多會發生周邊血管舒張，低血壓病患小心使用。
8. 本藥並不能阻止急性狹心症發作。
